After a year of treatment, tesamorelin didn't show a clear improvement in muscle energy recovery compared to a placebo in obese people with low growth hormone.
Scientific Claim
In a randomized controlled trial of 22 obese adults with reduced growth hormone secretion, 12 months of tesamorelin treatment did not result in a statistically significant difference in phosphocreatine recovery rate (ViPCr) compared to placebo (0.01 ± 3.76 vs. -1.02 ± 1.71 mM/min; P>0.10).
Original Statement
“After treatment with tesamorelin for 12 months, the change in ViPCr was 0.01 ± 3.76 vs −1.02 ± 1.71 mM/min (tesamorelin vs placebo, P > .10).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim states the observed result without causal language. 'Did not result in a statistically significant difference' is accurate.
Evidence from Studies
Supporting (0)
Contradicting (1)
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
Even though the average improvement in muscle energy recovery wasn’t dramatically different between the drug and placebo groups, people who got the drug and had higher IGF-I levels showed much better muscle recovery — meaning the drug likely helped, but the study didn’t highlight this connection in the claim.